	New content
International Journal of Toxicology

Free access

Research article

First published May 2002

Evaluation of the Carcinogenic Potential of Insulin Glargine (LANTUS) in Rats and Mice

Ingo Stammberger, Axel Bube, Beate Durchfeld-Meyer, Hans Donaubauer, and Gotz TroschauView all authors and affiliations

https://doi.org/10.1080/10915810290096306

Abstract

Insulin glargine (LANTUS) is a new, long-acting insulin analogue with a stable profile of action. The purpose of these studies was to evaluate the carcinogenic potential of insulin glargine in rats and mice. General toxicity studies were conducted in NMRI mice (3 months' duration) and rats (Wistar rats in the 3- and 6-month studies and Sprague-Dawley rats in the 12-month study) to determine the optimal dose of insulin glargine for long-term carcinogenicity studies. Based on these results, groups of Sprague-Dawley rats or NMRI mice (50 male, 50 female) received a daily subcutaneous dose of 2, 5, or 12.5 IU/kg of insulin glargine or 12.5 (mice) or 5 IU/kg (rats) of the reference insulin (NPH insulin) in a lifetime study. Similarly treated control and vehicle-control animals received isotonic sodium chloride (Na Cl) solution or the vehicle solution, respectively. In mice, the mortality rate was comparable between all groups. In rats, the mortality rate compared with the Na Cl control was significantly increased in the following groups: males treated with the vehicle control, all insulin glargine and NPH insulin groups, and in females in the high-dose insulin glargine and NPH insulin groups. There was no difference in the incidence of mammary tumors reported in both mice and rats when comparing the insulin glargine groups with the Na Cl, vehicle-control, or the NPH insulin groups. In rats and mice, the distribution of subcutaneous malignant fibrous histiocytomas found at the injection site were not dose-dependent. These lesions are a rodent-specific event and were related to chronic tissue irritation and inflammation. In rats, neuronal necrosis of the cerebrum was attributed to persistent repeated episodes of hypoglycemia induced by high doses of insulin. In these studies, there were no neoplastic findings to indicate that insulin glargine had a systemic carcinogenic potential in mice or rats.

References

Bahr, M., T. Kolter, G. Seipke, and J. Eckel. 1997. Growth promoting and metabolic activity of the human insulin analogue [Gly A21, Arg B31, Arg B32] insulin (HOE 901) in muscle cells. Eur. J. Pharmacol. 320:259–265.

Google Scholar

Berenblum, I. 1974. Carcinogenesis as a biological problem. Amsterdam: North Holland Publishing.

Google Scholar

Berti, L., M. Kellerer, B. Bossenmaier, E. Seffer, G. Seipke, and H. Haring. 1998. The long-acting human insulin analog HOE901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm. Metab Res. 30:123–129.

Google Scholar

Bornfeldt, K. E., R. A. Gidlof, A. Wasteson, M. Lake, A. Skottner, and H. J. Arnqvist. 1991. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34:307–313.

Google Scholar

Ciofetta, M., C. Lalli, P. D. Sindaco, E. Torlone, S. Pampanelli, L. Mauro, D. L. Chiara, P. Brunetti, and G. B. Bolli. 1999. Contribution of postprandial versus interprandial blood glucose to Hb A1C in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 22:795–800.

Google Scholar

Grasso, P., and L. Golberg. 1967. Subcutaneous sarcoma as an index of carcinogenic potency. Food Cosmet. Toxicol. 4:297–320.

Google Scholar

Greaves, P. 1990. Histopathology of preclinical toxicity studies: Interpretation and relevance in drug safety evaluation. Amsterdam: Elsevier Science.

Google Scholar

Greaves, P., and J. Faccini. 1981. Spontaneous fibrous histiocytic neoplasms in rats. Br. J. Cancer 43:402–411.

Google Scholar

Haseman, J., J. Bourbina, and S. Eustis. 1994. Effect of individual housing and other experimental design factors on tumour incidence in B6C3F1 mice. Fundam. Appl. Toxicol. 23:44–52.

Google Scholar

Home, P. D. 2000. Insulin gargine. A viewpoint by Philip D. Home. Drugs 59:261–262.

Google Scholar

Jorgensen, L., L. Dideriksen, and K. Drejer. 1992. Carcinogenic effect of the human insulin analogue B10Asp in female rats. Diabetologia 35 (Suppl 1): A3.

Google Scholar

Logothetopoulos, J. 1966. Electron microscopy of the pancreatic islets of the rat. Effects of prolonged insulin injections. Diabetes 15:823–829.

Google Scholar

Monro, A. 1993. How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk in humans? Adverse Drug React. Toxicol. Rev.. 12:5–34.

Google Scholar

Nielsen, F. S., L. N. Jorgensen, M. Ipsen, A. I. Voldsgaard, and H. H. Parving. 1995. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 38:592–598.

Google Scholar

Owens, D., P. Coates, S. Luzio, J. Tinbergen, and R. Kurzhals. 2000. Pharmacokinetics of [125]I-labelled insulin glargine (HOE 901) in healthy men. Diabetes Care 23:813–819.

Google Scholar

Pieber, T. R., I. Eugene-Jolchine, and E. Derobert. 2000. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE901 in type 1 diabetes. Diabetes Care 23:157–162.

Google Scholar

Ratner, R. E., I. B. Hirsch, J. L. Neifing, S. K. Garg, T. E. Mecca, and C. A. Wilson. 2000. Less hypoglycemia with insulin glargine in intensive insulin therapy for Type 1 diabetes. Diabetes Care 23:639–643.

Google Scholar

Rosenstock, J., G. Park, and J. Zimmerman. 2000. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 23:1137–1142.

Google Scholar

Rosskamp, R. 1997. Long-acting insulin analogs [abstract]. 16th IDF Congress, Helsinki.

Google Scholar

Suntzeff, V., R. Babcock, and L. Loeb. 1940. The development of sarcoma in mice following long continued injections of a buffered solution of hydrochloric acid. Am. J. Cancer 39:56–60.

Google Scholar

The United States Pharmacopeia. 1995. Rockville, MD: The National Formulary.

Google Scholar

Van Oosterhout, J., J. Van der Lann, E. De Waal, K. Olejniczak, M. Hilgenfeld, V. Schmidt, and R. Bass. 1997. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul. Toxicol. Pharmacol. 25:6–17.

Google Scholar

Yki-Jarvinen, H., A. Dressier, and M. Ziemen. 2000. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes. Diabetes Care 23:1130–1136.

Google Scholar

Zwicker, G., R. Eyster, D. Sells, and J. Gass. 1992. Spontaneous skin neoplasms in aged Sprague-Dawley rats. Toxicol. Pathol. 20:327–340.

Google Scholar

Cite article

If you have citation software installed, you can download article citation data to the citation manager of your choice

Information, rights and permissions

Information

Published In

International Journal of Toxicology

Volume 21, Issue 3

Pages: 171 - 179

Article first published: May 2002

Issue published: May 2002

Keywords

Rights and permissions

Request permissions for this article.

Request Permissions

PubMed: 12055018